Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma
BackgroundExtranodal natural killer T cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma with invariable infection of lymphoma cells with Epstein-Barr virus (EBV), and the presence of EBV-DNA in the blood is a well-known prognosticator. However, there is no consensus on which blood comp...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.594692/full |
id |
doaj-15fb193acf774f75b5f8a39ee47ef082 |
---|---|
record_format |
Article |
spelling |
doaj-15fb193acf774f75b5f8a39ee47ef0822020-12-08T08:38:47ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-11-011010.3389/fonc.2020.594692594692Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell LymphomaJoo Young Ha0Joo Young Ha1Hyungwoo Cho2Heungsup Sung3Ah Ra Jung4Yoon Sei Lee5Sang-Wook Lee6Jin-Sook Ryu7Eun Jin Chae8Kyung Won Kim9Jooryung Huh10Chan-Sik Park11Dong-Joon Kim12Seon-Ok Kim13Dok Hyun Yoon14Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDivision of Hematology/Medical Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South KoreaDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaBackgroundExtranodal natural killer T cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma with invariable infection of lymphoma cells with Epstein-Barr virus (EBV), and the presence of EBV-DNA in the blood is a well-known prognosticator. However, there is no consensus on which blood compartment is more optimal for predicting survival outcomes.MethodsWe analyzed 60 patients who were newly diagnosed with ENKTL from a prospectively collected database. EBV-DNA was measured in the whole-blood (WB) and plasma at the time of diagnosis and after treatment completion.ResultsEBV-DNA was detected in pre-treatment WB and plasma in 37 (61.7%) and 23 (38.3%) patients, respectively. The presence of pre-treatment plasma EBV-DNA was significantly associated with advanced stage while presence of WB EBV-DNA did not. Positivity of pre-treatment plasma-EBV, but not WB EBV-DNA, was independently associated with poor PFS (HR, 4.22;95% CI, 1.79–9.97; P=0.001) and OS (HR, 8.38; 95% CI, 3.03–23.19; P<0.001) in the multivariate analysis. After treatment completion, positivity of plasma-EBV was independently associated with poor PFS (HR, 9.41; 95% CI, 2.27–39.02; P=0.002) and OS (HR, 32.38; 95% CI, 3.25–322.56; P=0.003), whereas no significant association was observed between WB-EBV status and survival outcomes.ConclusionsOur results suggest that EBV-DNA in the plasma has better prognostic values than WB in patients with ENKTL.https://www.frontiersin.org/articles/10.3389/fonc.2020.594692/fullnon-Hodgkin lymphomaextranodal natural killer T cell lymphomaplasma EBV-DNAwhole-blood EBV-DNAprognosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joo Young Ha Joo Young Ha Hyungwoo Cho Heungsup Sung Ah Ra Jung Yoon Sei Lee Sang-Wook Lee Jin-Sook Ryu Eun Jin Chae Kyung Won Kim Jooryung Huh Chan-Sik Park Dong-Joon Kim Seon-Ok Kim Dok Hyun Yoon |
spellingShingle |
Joo Young Ha Joo Young Ha Hyungwoo Cho Heungsup Sung Ah Ra Jung Yoon Sei Lee Sang-Wook Lee Jin-Sook Ryu Eun Jin Chae Kyung Won Kim Jooryung Huh Chan-Sik Park Dong-Joon Kim Seon-Ok Kim Dok Hyun Yoon Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma Frontiers in Oncology non-Hodgkin lymphoma extranodal natural killer T cell lymphoma plasma EBV-DNA whole-blood EBV-DNA prognosis |
author_facet |
Joo Young Ha Joo Young Ha Hyungwoo Cho Heungsup Sung Ah Ra Jung Yoon Sei Lee Sang-Wook Lee Jin-Sook Ryu Eun Jin Chae Kyung Won Kim Jooryung Huh Chan-Sik Park Dong-Joon Kim Seon-Ok Kim Dok Hyun Yoon |
author_sort |
Joo Young Ha |
title |
Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma |
title_short |
Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma |
title_full |
Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma |
title_fullStr |
Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma |
title_full_unstemmed |
Superiority of Epstein-Barr Virus DNA in the Plasma Over Whole Blood for Prognostication of Extranodal NK/T Cell Lymphoma |
title_sort |
superiority of epstein-barr virus dna in the plasma over whole blood for prognostication of extranodal nk/t cell lymphoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2020-11-01 |
description |
BackgroundExtranodal natural killer T cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma with invariable infection of lymphoma cells with Epstein-Barr virus (EBV), and the presence of EBV-DNA in the blood is a well-known prognosticator. However, there is no consensus on which blood compartment is more optimal for predicting survival outcomes.MethodsWe analyzed 60 patients who were newly diagnosed with ENKTL from a prospectively collected database. EBV-DNA was measured in the whole-blood (WB) and plasma at the time of diagnosis and after treatment completion.ResultsEBV-DNA was detected in pre-treatment WB and plasma in 37 (61.7%) and 23 (38.3%) patients, respectively. The presence of pre-treatment plasma EBV-DNA was significantly associated with advanced stage while presence of WB EBV-DNA did not. Positivity of pre-treatment plasma-EBV, but not WB EBV-DNA, was independently associated with poor PFS (HR, 4.22;95% CI, 1.79–9.97; P=0.001) and OS (HR, 8.38; 95% CI, 3.03–23.19; P<0.001) in the multivariate analysis. After treatment completion, positivity of plasma-EBV was independently associated with poor PFS (HR, 9.41; 95% CI, 2.27–39.02; P=0.002) and OS (HR, 32.38; 95% CI, 3.25–322.56; P=0.003), whereas no significant association was observed between WB-EBV status and survival outcomes.ConclusionsOur results suggest that EBV-DNA in the plasma has better prognostic values than WB in patients with ENKTL. |
topic |
non-Hodgkin lymphoma extranodal natural killer T cell lymphoma plasma EBV-DNA whole-blood EBV-DNA prognosis |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2020.594692/full |
work_keys_str_mv |
AT jooyoungha superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT jooyoungha superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT hyungwoocho superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT heungsupsung superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT ahrajung superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT yoonseilee superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT sangwooklee superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT jinsookryu superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT eunjinchae superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT kyungwonkim superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT jooryunghuh superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT chansikpark superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT dongjoonkim superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT seonokkim superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma AT dokhyunyoon superiorityofepsteinbarrvirusdnaintheplasmaoverwholebloodforprognosticationofextranodalnktcelllymphoma |
_version_ |
1724390591544950784 |